(Q40378020)

English

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

scientific article published on 24 October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Allan Covens

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

John Blessing

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

David Bender

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Robert Mannel

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Mark Morgan

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gynecologic Oncology Group

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

24 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

586-590

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

The effect of hypoxia on the growth and radiation response of mammalian cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

The Effect of Hypoxia on the Generation Time of Mammalian Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Pre- and post-irradiation radiosensitization by SR 4233.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.09.032

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.09.032

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40378020&oldid=1896463473"